Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Kristinsson, Karl G
MetadataShow full item record
CitationSigurdsson S, Eythorsson E, Erlendsdóttir H, Hrafnkelsson B, Kristinsson KG, Haraldsson Á. Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland. Vaccine. 2020;38(12):2707–2714. doi:10.1016/j.vaccine.2020.01.094
AbstractIntroduction: Pneumococcus is an important respiratory pathogen. The 10-valent pneumococcal vaccine (PHiD-CV) was introduced into the Icelandic vaccination programme in 2011. The aim was to estimate the impact of PHiD-CV on paediatric hospitalisations for respiratory tract infections and invasive disease. Methods: The 2005-2015 birth-cohorts were followed until three years of age and hospitalisations were recorded for invasive pneumococcal disease (IPD), meningitis, sepsis, pneumonia and otitis media. Hospitalisations for upper- and lower respiratory tract infections (URTI, LRTI) were used as comparators. The 2005-2010 birth-cohorts were defined as vaccine non-eligible cohorts (VNEC) and 2011-2015 birth-cohorts as vaccine eligible cohorts (VEC). Incidence rates (IR) were estimated for diagnoses, birth-cohorts and age groups, and incidence rate ratios (IRR) between VNEC and VEC were calculated assuming Poisson variance. Cox regression was used to estimate the hazard ratio (HR) of hospitalisation between VNEC and VEC. Results: 51,264 children were followed for 142,315 person-years, accumulating 1,703 hospitalisations for the respective study diagnoses. Hospitalisations for pneumonia decreased by 20% (HR 0.80, 95%CI:0.67-0.95) despite a 32% increase in admissions for LRTI (HR 1.32, 95%CI:1.14-1.53). Hospital admissions for culture-confirmed IPD decreased by 93% (HR 0.07, 95%CI:0.01-0.50) and no hospitalisations for IPD with vaccine-type pneumococci were observed in the VEC. Hospitalisations for meningitis and sepsis did not change. A decrease in hospital admissions for otitis media was observed, but did not coincide with PHiD-CV introduction. Conclusion: Following the introduction of PHiD-CV in Iceland, hospitalisations for pneumonia and culture confirmed IPD decreased. Admissions for other LRTIs and URTIs increased during this period.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download
RightsCopyright © 2020. Published by Elsevier Ltd.
- Reduction in All-Cause Acute Otitis Media in Children <3 Years of Age in Primary Care Following Vaccination With 10-Valent Pneumococcal Haemophilus influenzae Protein-D Conjugate Vaccine: A Whole-Population Study.
- Authors: Sigurdsson S, Eythorsson E, Hrafnkelsson B, Erlendsdóttir H, Kristinsson KG, Haraldsson Á
- Issue date: 2018 Sep 28
- Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study.
- Authors: Eythorsson E, Sigurdsson S, Hrafnkelsson B, Erlendsdóttir H, Haraldsson Á, Kristinsson KG
- Issue date: 2018 Oct 4
- Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
- Authors: Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N
- Issue date: 2016 Nov 30
- Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
- Authors: Zhang XH, Leeuwenkamp O, Oh KB, Lee YE, Kim CM
- Issue date: 2018 Jan 2
- Comparison of Serotype Prevalence of Pneumococci Isolated from Middle Ear, Lower Respiratory Tract and Invasive Disease Prior to Vaccination in Iceland.
- Authors: Hjálmarsdóttir MÁ, Quirk SJ, Haraldsson G, Erlendsdóttir H, Haraldsson Á, Kristinsson KG
- Issue date: 2017